While Dorsomorphin treatment reduced MMP11+ mCAFs and suppressed tumor angiogenesis, its antitumor effects may also involve other mechanisms, such as reducing HSF1 activity or inhibiting ABCG2 function, as previously reported.[69, 70] Thus, attributing its effects solely to BMP2 inhibition in MMP11+ mCAFs remains challenging, and potential off‐target effects warrant further investigation. This evidence concerns the gene ABCG2 and neoplasm.